Biofunctionalized polymeric nanoparticles for the enhanced delivery of erlotinib in cancer therapy

Journal of Biomaterials Science Polymer Edition, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 26

Published: Nov. 23, 2024

Erlotinib, a potent epidermal growth factor receptor (EGFR) inhibitor, faces bioavailability challenges due to poor water solubility and stability. This study aims optimize erlotinib-loaded PLGA nanoparticles using 32 factorial design enhance drug delivery therapeutic efficacy. The effects of concentration (R1) NaTPP (R2) on nanoparticle characteristics, including particle size, zeta potential, polydispersity index (PDI), were investigated. optimal formulation (F5) was identified characterized, showing size 169.1 nm, potential 20.0 mV, PDI 0.146, indicating uniform stable nanoparticles. Transmission electron microscopy (TEM) confirmed spherical with minimal aggregation, while X-ray diffraction (XRD) indicated an amorphous state erlotinib. Formulation F5 demonstrated entrapment efficiency 81.9% yield 83.0%. In-vitro release studies revealed sustained pattern 90.0% cumulative at 48 h, following Zero Order kinetics. Cytotoxicity assays showed low cytotoxicity across various cell lines. Statistical analysis the significant impact variables properties. systematic optimization has successfully as candidate favorable high stability, controlled release, safe profile. Notably, optimized enhances efficacy through improved targeted delivery, addressing limitations conventional therapies. These findings suggest that hold for enhanced

Language: Английский

Improved epirubicin delivery selectivity to bladder cancer achieved by functionalized hydroxyethyl starch-based prodrug

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 293, P. 139275 - 139275

Published: Dec. 28, 2024

Language: Английский